Multifunctional osthole liposomes and brain targeting functionality with potential applications in a mouse model of Alzheimer's disease. (3rd July 2021)

• Record Type: Journal Article
• Authors: Ni, Ying-Nan; Kong, Liang; Li, Xue-Tao; Xiao, Hong-He; Wu, Yu-Tong; Liang, Xi-Cai; Lin, Ying; Li, Wan-Yi; Deng, Yan; Li, Yan; Shi, Yue; Cheng, Lan; Li, Hong-Yan; Ju, Rui-Jun; Yang, Jing-Xian
• Is Part Of: Journal of liposome research. Volume 31:Number 3(2021)
• Page Start: 267
• Page End: 278
• Publication Date: 2021-07-03
• Subjects: Alzheimer's disease -- osthole -- CXCR4 -- liposomes -- brain-targeting; Liposomes -- Periodicals; Liposomes -- Periodicals; 575.57
• DOI: 10.1080/08982104.2020.1806872
• Languages: English
• ISSNs: 0898-2104

Abstract

Abstract: Osthole (Ost) is a coumarin compound and a potential drug for Alzheimer's disease (AD). However, the effectiveness of Ost is limited by solubility, bioavailability, and low permeability of the blood-brain barrier. In this study, we constructed Ost liposomes with modified CXCR4 on the surface (CXCR4-Ost-Lips), and investigated the intracellular distribution of liposomes in APP-SH-SY5Y cells. In addition, the neuroprotective effect of CXCR4-Ost-Lips was examined in vitro and in vivo . The results showed that CXCR4-Ost-Lips increased intracellular uptake by APP-SH-SY5Y cells and exerted a cytoprotective effect in vitro . The results of Ost brain distribution showed that CXCR4-Ost-Lips prolonged the cycle time of mice and increased the accumulation of Ost in the brain. In addition, CXCR4-Ost-Lips enhanced the effect of Ost in relieving AD-related pathologies. These results indicate that CXCR4-modified liposomes are a potential Ost carrier to treat AD.